NCT02964364 China Takayasu Arteritis Registry (CTA Registry)
| NCT ID | NCT02964364 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aimin Dang |
| Condition | TAKAYASU ARTERITIS |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-08 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-08 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done. Our previous study supporting by National Natural Science Foundation of China indicated the cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity, and HLA gene alleles were associated with TA in Chinese han population. Further investigations with larger samples are needed to fully understand the a pathophysiology of TA. The purpose of this study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective disease monitoring and treatment strategies.
Eligibility Criteria
Inclusion Criteria: * Age at disease onset \< 40 years. (Development of symptoms or findings related to Takayasu arteritis at age \<40 years) * Claudication of extremities. (Development and worsening of fatigue and discomfort in muscles of 1 or more extremity while in use, especially the upper extremities) * Decreased brachial artery pulse. (Decreased pulsation of 1 or both brachial arteries) * BP difference \>10 mm Hg. (Difference of \>10 mm Hg in systolic blood pressure between arms) * Bruit audible on auscultation over 1 or both subclavian arteries or abdominal aorta. * Arteriogram abnormality. (Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes usually focal or segmental) Exclusion Criteria: * Vessel lesions that could be entirely due to atherosclerosis. * Giant cell arteritis or other infectious forms of large vessel vasculitis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02964364 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 80 Years, studying TAKAYASU ARTERITIS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02964364 currently recruiting?
Yes, NCT02964364 is actively recruiting participants. Contact the research team at aimindangfw@gmail.com for enrollment information.
Where is the NCT02964364 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT02964364 clinical trial?
NCT02964364 is sponsored by Aimin Dang. The trial plans to enroll 1,000 participants.